Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $1.61
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.46M
Market Cap
$152.86M
Enterprise Value$139.60M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 06, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Nov 29, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding220,416,320
10 Day Avg. Volume858,698
30 Day Avg. Volume1,456,130
Standard Deviation0.16
R-Squared0.16
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.57
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.87
Enterprise Value/Ebitda-6.83
Forecast
1Y Price Target
$4.67Price Target Upside586.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Lineage Therap News
PremiumCompany Announcements
Lineage Therap Issues Private Placement Securities
PremiumCompany Announcements
Lineage Therap Secures $66M Funding Through Direct Offering
PremiumCompany Announcements
Lineage Therap Announces $66 Million Direct Offering---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe start of the Phase 2 DOSED study brings OPC1 back into the clinic, aiming to improve on positive prior clinical effects in spinal cord injury patients.
Partnerships And CollaborationsLineage's collaboration with Eterna Therapeutics to develop hypoimmune pluripotent stem cell lines for neurology indications is progressing, with specific gene edits finalized for development.
Strategic PositioningLineage remains well ahead in its clinical progress compared to Eyestem and continues to lead and build momentum in the space.
Bears Say
Expectations And UncertaintiesPotential announcement for three-year Phase 1/2 data in the coming quarters could be an interesting catalyst, introducing uncertainty until results are disclosed.
Financial AdjustmentsThe company's 12-month price target has been lowered due to dilution from recent financing activities.
Market RisksRoche's upcoming Phase 2a data could serve as a significant catalyst for Lineage, reigniting enthusiasm for the company and putting OpRegen back in the spotlight, but also adding pressure for positive outcomes.
---
Ownership Overview
53.70% Insiders
6.38% Mutual Funds
0.79% Other Institutional Investors
32.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.48 and its highest was $1.61 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $152.86M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 12 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Nov 14, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.02.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. pays a Notavailable dividend of $0.112 which represents an annual dividend yield of N/A. See more information on Lineage Cell Therapeutics, Inc. dividends here
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 220,416,320 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -2.273%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
---
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (586.76% Upside)
$4.67 (586.76% Upside)
Hedge Fund Trend
Increased
By 9.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.2%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.42%
12-Months-Change
Fundamentals
Return on Equity
-29.95%
Trailing 12-Months
Asset Growth
-9.00%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
---
LCTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was generally positive with significant achievements such as extending the cash runway, progress with the FDA, increased revenue, and reduced net loss. However, there were some challenges, particularly regarding delays in the OPC1 study and manufacturing hurdles.Read More>---
LCTX Stock 12 Month Forecast
Average Price Target
$4.67
▲(586.76% Upside)
Technical Analysis
Mesoblast
―
Bluebird Bio
―
Fate Therapeutics
―
Sorrento Therapeutics
―
Cara Therapeutics
―
Best Analysts Covering LCTX
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
+14.28%
reiterated a buy rating 2 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +14.28% per trade.
---